Pilihan Terapi Definitif untuk Nodul Tiroid Otonom

Oleh :

dr. Ivana Dewi Mulyanto, SpKN(K), MKes, FANMB

Terapi definitif untuk kasus nodul tiroid otonom dipilih dengan tujuan utama menghilangkan tirotoksikosis dengan onset cepat dan durasi yang panjang. Nodul tiroid otonom adalah nodul jinak pada tiroid yang bekerja di luar sistem umpan balik negatif antara hipofisis dan kelenjar tiroid. Nodul tersebut dapat membesar dan menghasilkan hormon triiodotironin (T3) dan tiroksin (T4) tanpa stimulasi thyroid stimulating hormone (TSH).[1,2]

Kondisi tirotoksikosis dapat ditimbulkan oleh nodul tiroid yang berukuran minimal 2,5–3 cm. Etiologi terjadinya nodul tiroid otonom adalah mutasi somatik reseptor TSH, sedangkan mekanisme yang mencetuskan terjadinya mutasi tersebut masih belum jelas diketahui. Nodul tiroid otonom sering ditemukan pada pasien yang tinggal di daerah defisiensi iodium ringan hingga sedang.[1,2]

Diagnosis Nodul Tiroid Otonom

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Lam S, Lang BHH. A Review of the Pathogenesis and Management of Multinodular Goiter. Thyroid Disorders - Focus on Hyperthyroidism. InTech; 2014. DOI: 10.5772/57547. http://dx.doi.org/10.5772/57547
2. Muller K., Krohn K, et al. Effect of Iodine on Early Stage Thyroid Autonomy. Genomics 97. 2011; 94-100.
3. Moreno-Reyes R, Kyrilli A, et al. Is there still a role for thyroid scintigraphy in the workup of a thyroid nodule in the era of fine needle aspiration cytology and molecular testing?. version 1; referees: 3 approved. F1000Research 2016, 5. F1000 Faculty Rev:763. doi: 10.12688/f1000research.7880.1
4. Ronga G., Filesi M., et al. Autonomous Functioning Thyroid Nodules and 131I in Diagnosis and Therapy After 50 Years of Experience. Clin Nucl Med 2013; 38: 349-53.
5. Ross DS., Burch HB., et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10): 1343-420.
6. Lanitis S., Karkoulias K., et al. Type of Operation for Toxic Adenoma, Toxic Multinodular Goitre and Graves’ Disease. Hellenic J Surg. 2015; 87: 34-37.
7. Ravera S., Reyna-Neyra A., et al. The sodium/iodide symporter (NIS): molecular physiology and preclinical and clinical applications. Annu Rev Physiol. 2017; 79: 261-289.
8. Darrouzet E., Lindenthal S., et al. The Sodium/Iodide Symporter: State of the Arts of Its Molecular Characterization. Biochimia et Biophysoa Acta 1838. 2014; 244-253.
9. Filho RM., Ward LS., et al. Cumulative Doses of Radioiodine in the Treatment of Differentiated Thyroid Carcinoma: Knowing When to Stop. Arq Bras Endocrinol Metab. 2010; 54: 807-812.
10. Kahraman D., Kellert C., et al. Development of Hypothyroidism During Long-term Follow Up of Patients with Toxic Nodular Goitre after Radioiodine Therapy. Clin Endocrinol. 2012; 76: 297-303.
11. Felicio JS., Conceicao AMS., et al. Ultrasound-Guided Percutaneous Ethanol Injection Protocol to Treat Solid nad Mixed Thyroid Nodules. Frontiers in Endocrinology. 2016; 7(52): 1-6.
12. Anu Sharma. Vascularity Targeted Percutaneous Ethanol Injection of Toxic Adenomas: Outcomes of a Feasibility Study Performed in The USA. Endocrine Practice. 2019. DOI:10.4158/EP-2019-0329.
13. Sung JY., Baek JH., et al. Radiofrequency Ablation for Autonomously Functioning Thyroid Nodules: A Multicenter Study. Thyroid. 2015; 25(1).
14. Kim JH., Baek JH., et al. 2107 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. Korean J Radiol. 2018; 19(4): 632-655.
15. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician. 2012;58(2):158-162.